azacitidine has been researched along with Myeloproliferative Disorders in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 17 (53.13) | 24.3611 |
| 2020's | 14 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, K; Berger, D; Bettelheim, P; Gamperl, S; Greiner, G; Hoermann, G; Knöbl, P; Kornauth, C; Schiefer, AI; Schwarzinger, I; Sillaber, C; Smiljkovic, D; Sperr, WR; Staber, PB; Stefanzl, G; Thalhammer, R; Valent, P | 1 |
| Beach, CL; Döhner, H; Garcia-Manero, G; La Torre, I; Santini, V; Skikne, B; Wei, AH | 1 |
| Arnaud, B; Garnache Ottou, F; Hutin, P; Ianotto, JC; Laribi, K; Le Calloch, R; Le Clech, L; Salmon, F | 1 |
| Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I | 1 |
| Berthon, C; Carpentier, B; Chauvet, P; Goursaud, L; Lionne-Huyghe, P; Nibourel, O; Quesnel, B; Wemeau, M | 1 |
| Ambinder, AJ; Dalton, WB; DeZern, AE; Ghiaur, G; Gojo, I; Gondek, LP; Jain, T; Levis, MJ; Newman, M; Prince, GT; Sanber, K; Smith, BD; Tsai, HL; Webster, JA; Ye, K | 1 |
| Altrock, E; Costina, V; Darwich, A; Fabarius, A; Flach, J; Hofmann, WK; Jäger, E; Jann, JC; Jawhar, A; Jawhar, M; Kuzina, M; Levkin, PA; Marx, A; Metzgeroth, G; Neumaier, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Rapp, F; Riabov, V; Schmitt, N; Sens-Albert, C; Sperk, E; Steiner, L; Streuer, A; Weimer, N; Weis, CA; Wolf, J; Wuchter, P; Xu, Q | 1 |
| Dhangar, S; Ghatanatti, J; Mathan S, LP; Sawant, L; Shah, A; Shanmukhaiah, C; Vundinti, BR | 1 |
| Bernard, E; Chiba, S; Creignou, M; Handa, H; Hellström-Lindberg, E; Hiramoto, N; Imada, K; Ishikawa, T; Kakiuchi, N; Kasahara, S; Kiguchi, T; Kusakabe, M; Makishima, H; Miyano, S; Miyazaki, Y; Nakagawa, M; Nakamura, N; Nannya, Y; Naoe, T; Ogawa, S; Ohtake, S; Ohyashiki, K; Papaemanuil, E; Sato, S; Shibata, Y; Shiozawa, Y; Shiraishi, Y; Taguchi, M; Takaori-Kondo, A; Takeda, J; Tanaka, H; Tobiasson, M; Tsurumi, H; Usuki, K; Watanabe, M; Yoshida, K; Zhao, L | 1 |
| Al-Kali, A; Bogenberger, J; Dueck, AC; Hashmi, S; Hogan, W; Kosiorek, HE; Litzow, MR; Mesa, R; Palmer, J; Sproat, L; Tibes, R | 1 |
| Bobin, A; Cayssials E, E; Chomel, JC; Desmier, D; Gallego-Hernanz, P; Gardeney, H; Maillard, N; Moya, N; Systchenko, T; Torregrosa, J; Vonfeld, M | 1 |
| Fujita, J; Hirose, Y; Kamimura, R; Kiyohara, E; Nagate, Y; Nakaya, A; Nojima, S; Shibayama, H | 1 |
| Glavey, S; Kennedy, P; Moran, S; Murphy, PT; Quinn, J | 1 |
| De Moerloose, B; Decaluwe, W; Flotho, C; Hofmans, M; Lammens, T; Niemeyer, C; Philippé, J; Schröder, R; Van Roy, N | 1 |
| Dasanu, CA; Lerner, J; Michel, M | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Elliott, MA; Foran, JM; Gangat, N; Guglielmelli, P; Hanson, CA; Litzow, MR; Mannelli, F; Palmer, JM; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vannucchi, AM | 1 |
| Ragon, BK; Savona, MR | 1 |
| Almohareb, F; El Fakih, R; Hassanein, M; Komrokji, R; Rasheed, W; Shaheen, M | 1 |
| Curtis, SA; Folkers, A; Medoff, E; Mixon, R; Shallis, RM; Xu, ML; Zeidan, AM | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Anaclerico, B; Andriani, A; Aroldi, A; Breccia, M; Carmosino, I; Centra, A; Di Veroli, A; Elli, E; Fianchi, L; Foà, R; Latagliata, R; Martini, V; Montanaro, G; Montanaro, M; Niscola, P; Trapè, G; Villivà, N; Voso, MT | 1 |
| Blanco, ML; Brunet, S; Bussaglia, E; Carricondo, M; Esquirol, A; García-Cadenas, I; Garrido, A; Gich, I; Hoyos, M; Martino, R; Nomdedéu, JF; Pratcorona, M; Santaliestra, M; Sierra, J | 1 |
| Ahmann, G; Azorsa, DO; Bogenberger, JM; Braggio, E; Camoriano, J; Cardone, M; Choudhary, A; Chow, D; Coombes, KR; Fauble, V; Gonzales, IM; Kornblau, SM; Lena, R; Mantei, J; Mesa, RA; Pierceall, WE; Qiu, YH; Shi, CX; Stewart, AK; Tibes, R; Tiedemann, RE; Valdez, R; Yin, H | 1 |
| Galli, S; Harrison, CN; Keohane, C; McLornan, DP; Mwirigi, A; Radia, DH; Raj, K | 1 |
| Abdel-Wahab, O; Ahn, J; Armstrong, SA; Chiosis, G; Chung, YR; Dogan, A; Hricik, T; Intlekofer, A; Levine, RL; Lipson, D; Manshouri, T; McKenney, AS; Miller, VA; Nahas, M; Otto, GA; Pandey, S; Park, CY; Rampal, R; Rapaport, F; Stephens, PJ; van den Brink, MR; Verstovsek, S; Wang, K; Yelensky, R | 1 |
| Chen, H; Gao, SM; Li, HY; Tang, LY; Wu, JB; Yang, JJ; Zheng, XQ | 1 |
| Cerquozzi, S; Daly, A; Khwaja, R; Mahé, E; Owen, C; Wong, M | 1 |
| Adès, L; Chait, Y; Cluzeau, T; Dartigeas, C; Delaunay, J; Dreyfus, F; Eclache, V; Fenaux, P; Harel, S; Itzykson, R; Kiladjian, JJ; Quesnel, B; Raffoux, E; Salanoubat, C; Sanhes, L; Seegers, V; Sorin, L; Thepot, S; Turlure, P | 1 |
| Bolaños-Meade, J; Fuchs, EJ; Gore, SD; Jones, RJ; Luznik, L; McDevitt, MA; Smith, BD | 1 |
| Chim, CS; Drexler, HG; Fung, TK; Wan, TS; Wong, KF; Wong, KY | 1 |
| Atenafu, EG; Brandwein, JM; Craddock, KJ; Gupta, V; Kennedy, JA; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Bayar, E; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Lyons, J; Mannari, R; Rosenfeld, CS; Thomas, D | 1 |
4 review(s) available for azacitidine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloproliferative Disorders; Randomized Controlled Trials as Topic | 2022 |
The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Topics: Adult; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; World Health Organization | 2017 |
Azacitidine Use for Myeloid Neoplasms.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders | 2018 |
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood Transfusion; Breast Neoplasms; Female; Humans; Hydroxyurea; Isocitrate Dehydrogenase; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms, Second Primary; Treatment Refusal | 2018 |
3 trial(s) available for azacitidine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Treatment Outcome | 2023 |
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Prognosis; Treatment Outcome | 2010 |
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Differentiation; Child; Child, Preschool; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Female; Gene Silencing; Hematologic Neoplasms; Humans; Karyotyping; Leukemia; Male; Methylation; Middle Aged; Myeloproliferative Disorders; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2004 |
25 other study(ies) available for azacitidine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Basophils; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms, Second Primary; Prognosis | 2021 |
Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Topics: Aged, 80 and over; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Female; Humans; Myeloproliferative Disorders; Skin Neoplasms; Sulfonamides | 2022 |
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Retrospective Studies; Transplantation Conditioning | 2022 |
Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
Topics: Azacitidine; Humans; Janus Kinase 2; Leukemia; Lymphocyte Activation; Mutation; Myeloproliferative Disorders; Neoplasms; Recurrence | 2022 |
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides | 2023 |
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Topics: Animals; Azacitidine; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Mice; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Protein-Lysine 6-Oxidase | 2023 |
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.
Topics: Azacitidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2023 |
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Prognosis; Treatment Outcome | 2023 |
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Topics: Aged; Aged, 80 and over; Azacitidine; Blast Crisis; Humans; Myeloproliferative Disorders; Quality of Life; Treatment Outcome | 2023 |
Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
Topics: Aged; Aged, 80 and over; Azacitidine; Dendritic Cells; Humans; Male; Myeloproliferative Disorders; Neutropenia; Skin Neoplasms | 2023 |
Wilms' tumor and preferentially expressed antigen of melanoma in patients with myeloid neoplasms treated with azacytidine.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Humans; Myeloproliferative Disorders; Prognosis; Treatment Outcome; WT1 Proteins | 2019 |
Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making.
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Clinical Decision-Making; DNA Methylation; Humans; Infant; Infant, Newborn; Male; Myeloproliferative Disorders; Noonan Syndrome | 2019 |
5-azacitidine reversing "spent" phase polycythemia vera back to proliferative phase and need for phlebotomy.
Topics: Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Female; Humans; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera | 2020 |
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Melphalan; Middle Aged; Mutation; Myeloproliferative Disorders; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome | 2019 |
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Transplantation, Homologous; Treatment Outcome; WT1 Proteins | 2019 |
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; bcl-X Protein; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cell Leukemia Sequence 1 Protein; Myeloproliferative Disorders; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides | 2014 |
Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Hematologic Neoplasms; Humans; Male; Myeloproliferative Disorders; Nitriles; Pyrazoles; Pyrimidines | 2014 |
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Topics: Animals; Azacitidine; Benzodioxoles; Blotting, Western; Colony-Forming Units Assay; Decitabine; Exome; Flow Cytometry; Hematologic Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Purines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2014 |
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Western; Case-Control Studies; Decitabine; DNA Methylation; Epigenomics; Humans; Janus Kinase 2; Molecular Sequence Data; Mutation; Myeloproliferative Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT3 Transcription Factor; Tumor Cells, Cultured | 2015 |
Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases.
Topics: Aged; Aged, 80 and over; Azacitidine; Dendritic Cells; Female; Humans; Male; Myeloproliferative Disorders; Neoadjuvant Therapy; Treatment Outcome | 2016 |
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
Topics: Adult; Aged; Azacitidine; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloproliferative Disorders; Prospective Studies; Remission Induction; Salvage Therapy; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Base Sequence; Bone Marrow Neoplasms; Case-Control Studies; Cell Line, Tumor; Demography; DNA Methylation; Female; Humans; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Myeloproliferative Disorders; Philadelphia Chromosome | 2011 |
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Registries; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |